Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumours 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour Refractory to Conventional Treatment 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1Advanced Solid Malignancies 1

Interventions

Docetaxel 6Erlotinib Hydrochloride 5Cetuximab 5Magnetic Resonance Spectroscopy 4Radiotherapy 3Cisplatin 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2SS1(dsFv)PE38 2Radiation 2Paclitaxel 2Immunohistochemistry 2Hydroxyurea 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Everolimus 2Carboplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1sargramostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Salivary Gland Neoplasms × ceralasertib × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡